U.S. House Directs VA to Expand Neurostimulation Research for Traumatic Brain Injury
Event summary
- U.S. House Appropriations Committee report language directs VA to support research on non-invasive deep brain neurostimulation for treatment-resistant TBI.
- Nexalin Technology's Nexalin America division championed the legislative provision included in the Fiscal Year 2027 Military Construction, Veterans Affairs, and Related Agencies Appropriations bill.
- The bill passed the U.S. House of Representatives with a 400-15 vote and includes $945 million for VA Medical Research.
- Nexalin's DIFS™ waveform is positioned to meet the VA’s directive for non-invasive deep brain stimulation.
The big picture
The U.S. House’s directive marks a strategic shift toward non-invasive neurostimulation as a viable treatment for veterans with treatment-resistant TBI. This aligns with broader trends in mental health innovation, where non-pharmacologic solutions are gaining traction. The provision’s inclusion in a bill with $945 million allocated for VA Medical Research underscores the potential scale of future adoption. Nexalin’s advocacy through its Nexalin America division positions the company at the forefront of this emerging therapeutic category.
What we're watching
- Regulatory Validation
- Whether the Congressional directive will accelerate regulatory pathways for Nexalin’s DIFS™ technology within the VA.
- Clinical Adoption
- The pace at which the VA integrates non-invasive deep brain neurostimulation into treatment protocols for TBI.
- Market Differentiation
- How Nexalin’s DIFS™ waveform will distinguish itself from traditional neurostimulation devices in the VA’s evaluation.
Related topics